-
Intensity Therapeutics NasdaqCM:INTS Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Location: 1 Enterprise Drive, Shelton, CT, 06484-4779, United States | Website: https://www.intensitytherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
5.085M
Cash
929K
Avg Qtr Burn
-3.211M
Short % of Float
2.31%
Insider Ownership
33.62%
Institutional Own.
14.16%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INT230-6 Details Advanced Soft tissue sarcomas | Phase 3 Data readout | |
INT230-6 Details Neoadjuvant Triple-negative breast cancer | Phase 2 Data readout | |
INT230-6 w/ Keytruda Details Pancreatic cancer, Colorectal cancer | Phase 2 Data readout | |
INT230-6 Details Breast cancer | Phase 2 Update | |
INT230-6 w/ Yervoy Details Liver cancer, Sarcoma, Breast cancer | Phase 2 Update |